The Forgotten Cancers Project was designed to facilitate research into less common cancers. Cancer Council Victoria researchers are currently collaborating with two international consortia, the Pancreatic Cancer Case Control Consortium (PanC4) and the International Lymphoma Epidemiology Consortium (InterLymph).
The Pancreatic Cancer Case Control Consortium is currently investigating the inflammatory potential of diet and how it may interact with related genes in the development of pancreatic cancer. It is known that about one-fourth of all pancreatic cancers are attributable to cigarette smoking, which is highly pro-inflammatory. Other risk factors for pancreatic cancer include inflammatory diseases like chronic pancreatitis, long-standing diabetes, and potentially obesity, which correlates positively with chronic inflammation and may increase risk for pancreatic cancer. PanC4 aims to examine the role of diet-derived inflammation in pancreatic cancer. Preliminary research findings suggest that an inflammatory diet may act in synergy with cigarette smoking and long-standing diabetes (≥5 years) to increase the risk of pancreatic cancer beyond that of each factor alone. The next stage of this research will focus on inflammation-related genes and whether they act in combination with diet-derieved inflammation to influence the risk of pancreatic cancer. Data from FCP will be contributed toward a case-control analysis of pooled data.
The InterLymph Consortium, or the International Consortium of Investigators Working on Non-Hodgkin's Lymphoma Epidemiologic Studies, is a group of international investigators researching lymphoid malignancies such as non-Hodgkin's lymphoma and multiple myeloma. In recent years, genome-wide association studies (GWAS) and pooled analyses have enabled great progress in identifying genetic variants associated with risk of specific non-Hodgkin lymphoma (NHL) subtypes. InterLymph plans to build and capitalise on this progress by conducting a larger and more comprehensive GWAS to identify the genetic variants that contribute to the development of NHL and influence survival. It is hoped that in turn this will more fully explain familial risk of NHL. The Forgotten Cancers Project is a collaborating partner in this research, which will include data from 22 studies on around 9,000 people with non-Hodgkin lymphoma. This will then be expanded to include other types of lymphoid malignancies.